Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtre
Ajouter des filtres








Gamme d'année
1.
Rev. argent. microbiol ; 32(3): 136-143, jul.-sept. 2000.
Article Dans Anglais | LILACS | ID: lil-332524

Résumé

Dihydrolipoamide dehydrogenase (LADH) from Trypanosoma cruzi, the causative agent of Chagas' disease, was inactivated by treatment with myeloperoxidase (MPO)-dependent systems. LADH lipoamide reductase and diaphorase activities decreased as a function of incubation time and composition of the MPO/H2O2/halide system, a transient increase preceding the loss of diaphorase activity. Iodide, bromide, thiocyanide and chloride were effective components of MPO/H2O2 or MPO/NADH systems. Catalase prevented LADH inactivation by the MPO/NADH/halide systems in agreement with H2O2 production by NADH-supplemented LADH. Thiol compounds (L-cysteine, N-acetylcysteine, penicillamine, N-(2-mercaptopropionylglycine) and Captopril prevented LADH inactivation by the MPO/H2O2/NaCl system and by NaOCl, thus supporting HOCl as agent of the MPO/H2O2/NaCl system. MPO/H2O2/NaNO2 and MPO/NADH/NaNO2 inactivated LADH, the reaction being prevented by MPO inhibitors and thiol compounds. T. cruzi LADH was affected by MPO-dependent systems like myocardial LADH, allowance being made for the variation of the diaphorase activity and the greater sensitivity of the T. cruzi enzyme to MPO/H2O2/halide systems.


Sujets)
Animaux , Humains , Acide hypochloreux/pharmacologie , Dihydrolipoamide dehydrogenase , Granulocytes neutrophiles/physiologie , Nitrites , Myeloperoxidase , Protéines de protozoaire/antagonistes et inhibiteurs , Stimulation du métabolisme oxydatif , Trypanosoma cruzi , Acétylcystéine/pharmacologie , Acide lipoïque/analogues et dérivés , Acide lipoïque/métabolisme , Bromures , Captopril , Catalase , Cystéine/pharmacologie , Chlorure de sodium/pharmacologie , Composés du sodium/pharmacologie , Cytotoxicité immunologique , Espèces réactives de l'oxygène/métabolisme , Glutathion , Glycine , Cinétique , Myocarde , NAD , Granulocytes neutrophiles/enzymologie , Oxydoréduction , Pénicillamine , Peroxyde d'hydrogène/pharmacologie , Protéines recombinantes/antagonistes et inhibiteurs , Thiols , Tryptophane , Tyrosine
2.
Experimental & Molecular Medicine ; : 87-92, 1998.
Article Dans Anglais | WPRIM | ID: wpr-70154

Résumé

MDR1 promoter has been shown to contain heat shock elements (HSE), and it has been reported that FM3A/M and P388/M MDR cells show a constitutively activated heat shock factor (HSF), suggesting that HSF might be an important target for reversing the multidrug resistance. Therefore, it was examined whether quercetin, which has been shown to interfere with the formation of the complex between HSE and HSF, and to downregulate the level of HSF1, can sensitize MDR cells against anticancer drugs by inhibition of HSF DNA-binding activity. In this study, quercetin appeared to inhibit the constitutive HSF DNA-binding activity and the sodium arsenite-induced HSF DNA-binding activity in the MDR cells. The basal and sodium arsenite-induced MDRCAT activities were remarkably suppressed by the treatment of quercetin. These results were well consistent with the finding that the treatment of quercetin decreased the expression level of P-gp, MDR1 gene product, in dose-dependent manner, and markedly increased the sensitivity of MDR cells to vincristine or vinblastine. These results suggest that quercetin can decrease the expression of P-gp via inhibition of HSF DNA-binding activity, and might be useful as a chemosensitizer in MDR cells.


Sujets)
Souris , Animaux , Antinéoplasiques/pharmacologie , Arsénites/pharmacologie , Carcinomes/traitement médicamenteux , Multirésistance aux médicaments/physiologie , Résistance aux médicaments antinéoplasiques/physiologie , Protéines du choc thermique/métabolisme , Protéines du choc thermique/effets des médicaments et des substances chimiques , Protéines du choc thermique/antagonistes et inhibiteurs , Leucémie expérimentale/traitement médicamenteux , Glycoprotéine P/génétique , Glycoprotéine P/effets des médicaments et des substances chimiques , Quercétine/pharmacologie , Composés du sodium/pharmacologie , Cellules cancéreuses en culture , Vinblastine/pharmacologie , Vincristine/pharmacologie
3.
Indian J Exp Biol ; 1993 Jun; 31(6): 529-32
Article Dans Anglais | IMSEAR | ID: sea-61584

Résumé

Intestinal uptake of lysine in rats progressively decreased with an increase in pH from 5.2 to 8.5, both in the presence and absence of Na+ ions. At pH 5.2 lysine uptake was 30-35% more than that at neutral pH. Na+ activated lysine uptake by 40-50% at pH 5.2 and it was increased to 110-120% at neutral pH. The observed increase in lysine uptake in response to Na+ and H+ gradients was due to enhanced maximal velocity (Vmax), with little change in affinity constant (Kt). Arrhenius analysis revealed a biphasic curve for lysine uptake with transition temperature (Tc) around 20 degrees C (24 degrees C at pH 5.2 in presence of Na+). The energy of activation (Ea) below (16.1-23.4 Kcal/mole) and above (6.7-8.6 Kcal/mole) the Tc was similar at pH 5.2 and 7.0 both in the presence and absence of Na+ ions. The sensitivity of lysine uptake to various inhibitors was also dependent upon pH and Na+ ions.


Sujets)
Animaux , Arsénites/pharmacologie , Dinitrophénols/pharmacologie , N-Éthyl-maléimide/pharmacologie , Harmaline/pharmacologie , Concentration en ions d'hydrogène , Absorption intestinale/effets des médicaments et des substances chimiques , Iodo-acétates/pharmacologie , Acide iodo-acétique , Isatine/pharmacologie , Lysine/pharmacocinétique , Mâle , Rats , Rat Wistar , Sodium/pharmacologie , Composés du sodium/pharmacologie , Antiport des ions sodium-hydrogène/métabolisme
SÉLECTION CITATIONS
Détails de la recherche